TruSight Oncology 500
Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples. Read More...
TruSight Oncology 500 is a next-generation sequencing (NGS) assay that enables Comprehensive Genomic Profiling of tumor samples. It supports identification of all relevant DNA and RNA* variants implicated in various tumor types.
In addition, it accurately measures the key immunotherapy biomarkers: tumor mutation burden (TMB) and microsatellite instability (MSI).
Save Time, Money, and Samples through assay Consolidation
Achieve Highly Confident Results
Unlock Immuno-Oncology
* The product to evaluate DNA & RNA variants is the TSO500 DNA/RNA bundle.
| Pan-Cancer Biomarkers NTRK1 NTRK2 NTRK3 MSI TMB (Emerging) |
||||||||
|---|---|---|---|---|---|---|---|---|
| Lung | Melanoma | Colon | Ovarian | Breast | Gastric | Bladder | Myeloid | Sarcoma |
| AKT1 | BRAF | AKT1 | BRAF | AKT1 | BRAF | MSH5 | ABL1 | ALK |
| ALK | CTNNB1 | BRAF | BRCA1 | AR | KIT | PMS2 | ASX1 | APC |
| BRAF | GNA11 | HRAS | BRCA2 | BRCA1 | KRAS | TSC1 | CALR | BRAF |
| DDR2 | GNAQ | KRAS | KRAS | BRCA2 | MET | CEBPA | CDK4 | |
| EGFR | KIT | MET | PDGFRA | ERBB2 | MLH1 | ETV6 | CTNNB1 | |
| ERBB2 | MAP2K1 | MLH1 | FOXL2 | FGFR1 | PDGFRA | EZH2 | ETV6 | |
| FGFR1 | NF1 | MSH2 | TP53 | FGFR2 | TP53 | FLT3 | EWSR1 | |
| FGFR3 | NRAS | MSH6 | PIK3CA | GATA2 | FOXO1 | |||
| KRAS | PDGFRA | NRAS | PTEN | IDH1 | GLI1 | |||
| MAP2K1 | PIK3CA | PIK3CA | IDH2 | KJT | ||||
| MET | PTEN | PMS2 | JAK2 | MDM2 | ||||
| NRAS | TP53 | PTEN | KIT | MYOD1 | ||||
| PIK3CA | SMAD4 | MPL | NAB2 | |||||
| PTEN | TP53 | NPM1 | NF1 | |||||
| RET | RUNX1 | PAX3 | ||||||
| TP53 | SF3B1 | PAX7 | ||||||
| TMB | SRSF2 | PDGFRA | ||||||
| TP53 | PDGFRB | |||||||
| SDHB | ||||||||
| SDHC | ||||||||
| SMARCB1 | ||||||||
| TFE3 | ||||||||
| WT1 | ||||||||
The genes and biomarkers listed in this table are a subset of all genes included in the panel. In order to view the full gene list, please download the product datasheet, available under Literature in this page.
* The product to evaluate DNA & RNA variants is the TSO500 DNA/RNA bundle.
Input Recommendations for TMB, MSI, and Small Variant Analysis with TruSight Oncology 500
Technical Note | HTML
Analysis of TMB and MSI Status with TruSight Oncology 500
Application Note | HTML
Analysis of TruSight Oncology 500 data with PierianDx Clinical Genomics Workspace Software
Brochure | PDF< 1 MB
TruSight Oncology 500 Demo Program Flyer
Brochure | PDF< 1 MB
TruSight Oncology 500 datasheet
Data Sheet | HTML
Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.
TruSight Oncology is a set of NGS platform reagents for the detection of cancer variants, using an enrichment-based method to simultaneously analyze DNA and RNA. Gene content is not included.
Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.
